| pubmed-article:8339262 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8339262 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8339262 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:8339262 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:8339262 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:8339262 | lifeskim:mentions | umls-concept:C1521871 | lld:lifeskim |
| pubmed-article:8339262 | lifeskim:mentions | umls-concept:C0444498 | lld:lifeskim |
| pubmed-article:8339262 | lifeskim:mentions | umls-concept:C0332120 | lld:lifeskim |
| pubmed-article:8339262 | pubmed:issue | 15 | lld:pubmed |
| pubmed-article:8339262 | pubmed:dateCreated | 1993-9-2 | lld:pubmed |
| pubmed-article:8339262 | pubmed:abstractText | We have derived from lymphocytes infiltrating a human regressive melanoma lesion a series of T-cell receptor alpha/beta-dependent, HLA-B14-restricted cytotoxic T-lymphocyte clones reactive against the autologous tumor. Analysis of the T-cell receptor gene expression revealed that all the clones represented a unique cell expressing a V beta 13.1/J beta 1.1 gene segment. T-cell receptor transcripts expressed in the cloned cells were compared to those present in the uncultured tumor tissue. This analysis demonstrated that the specific cytotoxic T-lymphocyte clones characterized in vitro was actually selected and amplified in vivo at the lesion site. These results provide strong evidence that effector T-cells have contributed to tumor regression. | lld:pubmed |
| pubmed-article:8339262 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8339262 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8339262 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8339262 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8339262 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8339262 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8339262 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8339262 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:8339262 | pubmed:author | pubmed-author:FaureFF | lld:pubmed |
| pubmed-article:8339262 | pubmed:author | pubmed-author:TriebelFF | lld:pubmed |
| pubmed-article:8339262 | pubmed:author | pubmed-author:MackensenAA | lld:pubmed |
| pubmed-article:8339262 | pubmed:author | pubmed-author:HercendTT | lld:pubmed |
| pubmed-article:8339262 | pubmed:author | pubmed-author:FerradiniLL | lld:pubmed |
| pubmed-article:8339262 | pubmed:author | pubmed-author:VielSS | lld:pubmed |
| pubmed-article:8339262 | pubmed:author | pubmed-author:CarcelainGG | lld:pubmed |
| pubmed-article:8339262 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8339262 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:8339262 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:8339262 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8339262 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8339262 | pubmed:pagination | 3569-73 | lld:pubmed |
| pubmed-article:8339262 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:meshHeading | pubmed-meshheading:8339262-... | lld:pubmed |
| pubmed-article:8339262 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8339262 | pubmed:articleTitle | Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. | lld:pubmed |
| pubmed-article:8339262 | pubmed:affiliation | Laboratoire d'Hemato-Immunologie, INSERM U333, Institut Gustave Roussy, Villejuif, France. | lld:pubmed |
| pubmed-article:8339262 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8339262 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8339262 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8339262 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8339262 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8339262 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8339262 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8339262 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8339262 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8339262 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8339262 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8339262 | lld:pubmed |
